Evercore ISI Trims AbbVie Price Target to $228, Maintains Outperform Rating

Evercore ISI has lowered its price target for AbbVie (ABBV) to $228 from $232 following the company's latest quarterly performance. Despite the slight reduction, analyst Gavin Clark-Gartner maintained an 'Outperform' rating on the pharmaceutical giant's stock. The adjustment follows Q4 earnings that exceeded profit estimates, primarily driven by robust sales of its blockbuster drug Humira. However, a revenue shortfall from Rinvoq has introduced some caution regarding the company's immediate growth trajectory. The analyst noted that consensus expectations for 2026 and 2027 remain beatable, suggesting long-term potential remains intact. This move reflects a recalibration of short-term expectations while preserving a positive outlook on AbbVie's fundamental strength. Investors continue to monitor the company's ability to offset Humira's biosimilar competition through its newer immunology portfolio.